Philipp M. Krabusch

Quality of life outcomes in two phase 3 trials of setmelanotide in patients with obesity due to LEPR or POMC deficiency

K. Clément, A. Gnanasakthy, C. Poitou, 2022, Orphanet Journal of Rare Diseases.

Early-set POMC methylation variability is accompanied by increased risk for obesity and is addressable by MC4R agonist treatment

B. Obermayer, A. Prentice, K. Jöckel, 2023, Science Translational Medicine.

Cardiac phenotype and tissue sodium content in adolescents with defects in the melanocortin system.

M. Kelm, R. Cone, T. Kuehne, 2021, The Journal of clinical endocrinology and metabolism.

Long-term outcomes of bariatric surgery in patients with bi-allelic mutations in the POMC, LEPR, and MC4R genes.

K. Clément, F. Pattou, S. Wiegand, 2021, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials.

W. Chung, K. Clément, I. Farooqi, 2020, The lancet. Diabetes & endocrinology.